Genprex to Present at Two Upcoming Conferences

AUSTIN, Texas, March 27, 2017 — Genprex, Inc., a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, today announced that Julien Pham, MD, the Company’s Chief Operating Officer, is scheduled to present a corporate overview at two upcoming healthcare investor conferences.

Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 PM EDT in New York, NY

BioCentury 24th Annual Future Leaders in Biotech Industry – Friday, April 7, 2017 at 11:20 AM EDT in New York, NY

About Genprex

Genprex is a privately held, clinical-stage biopharmaceutical company developing immunogene therapy treatments to increase the treatment options for various cancers. Genprex’s lead product candidate, Oncoprex, has shown synergistic anti-cancer activity when combined with EGFR inhibitors and other drugs.  The company is also working with world-class institutions and collaborators to in-license and develop further drug candidates. Genprex controls a portfolio of 30 issued and 6 pending patents covering tumor suppressors, therapeutics, diagnostics, nanovesicle delivery systems, and manufacturing processes. The company was founded in 2009 and is headquartered in Austin, Texas.  For more information, please visit or

Stephanie Carrington
ICR Healthcare
[email protected]

James Heins
ICR Healthcare
[email protected]